编号：20210003 号 证券代码：002570 证券简称：贝因美 贝因美股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-------------------------------------|----------------------------------------------------------------------| | | □特定对象调研 | ■分析师会议 | | | | □媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 信达证券，食品饮料分析师，马铮 | | | 时间 2021 | 年 6 月 11 日 | 11:00-12:00 | | | 地点 贝因美大厦会议室电话会议 | | | | 董事会秘书 李志容 | | | 上市公司接待人 员姓名 | 策略师 刘文春 证券事务代表 黄鹂 | | | | | 【李志容女士介绍了公司的战略发展思 ...

编号：20210002 号 证券代码：002570 证券简称：贝因美 贝因美股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------|------------------------------------------------------------------------------|------------------------------------------------| | | | | | | □特定对象调研 | ■分析师会议 | | | □媒体采访 □业绩说明会 | | | 投资者关系活 动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | | | Citigroup Global Market, Jane Guo\Tiffany Feng | | | Southern Fund, Kang | Shao | | | Janus Henderson Investors, May Ling | Wee | | | Blackrock, YiTay Hui ...

证券代码：002570 证券简称：贝因美 编号：20210006 号 贝因美股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------- ...

编号：20210005 号 证券代码：002570 证券简称：贝因美 贝因美股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------| | | | | | | □特定对象调研 ■分析师会议 | | | | □媒体采访 □业绩说明会 | | | 投资者关系活动 类别 | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 （请文字说明其他活动内容） | | | | 浙商证券食品饮料分析师 | 孙天一 | | 参与单位名称及 人员姓名 | 浙商证券 食品饮料分析师 中信建投 食品饮料分析师 ...

证券代码：002570 证券简称：贝因美 贝因美股份有限公司 投资者关系活动记录表 编号：20210008 号 | --- | --- | --- | |---------------------|---------------------------|-------------------------------------------------------------------------------| | | | | | | □特定对象调研 | ■分析师会议 | | | | □媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 | 马铮 信达证券食品饮料行业 | 首席分析师 | | 人员姓名 | 程丽丽 | 信达证券食品饮料行业 研究员 | | | 苏香 摩根士丹利华鑫基金 | 助理研究员 | | 时间 2021 | 年 11 月 23 日 | 16:00 | | 地点 电话会议 | | | | 上市公司接待人 | 董事会秘书 李志容 | | | 员姓名 | 经 ...

Financial Performance - In 2021, the company achieved a revenue of 2.54 billion CNY, a decrease of 4.71% compared to 2020 [3] - The net profit attributable to shareholders was 73.31 million CNY, an increase of 122.61% from 2020 [3] - In Q1 2022, the company reported a revenue of 814 million CNY, a growth of 43.68% year-on-year [3] - The net profit attributable to shareholders in Q1 2022 was 20.13 million CNY, up by 38.45% compared to the same period last year [3] - Operating cash flow net amount reached 246.74 million CNY, an increase of 713.34% year-on-year [3] Company Strategy and Innovation - The company focuses on enhancing channel strength, consolidating existing markets, and expanding new markets to improve performance [3] - The founder's return as general manager has led to comprehensive reforms and innovations within the company [3] - The company is committed to maintaining its core competitive advantages in R&D, product quality, and brand management [4] Industry Outlook - The maternal and infant industry is characterized by high safety standards and strong consumer demand, with expectations of a rebound in birth rates post-pandemic [4] - New national standards and trends are expected to provide structural growth opportunities for domestic brands [4] Product Development and Compliance - The company has submitted 15 series of 45 infant formula registrations in compliance with new national standards [4] - Product innovation focuses on high-quality raw materials, advanced processes, and scientific formulations [4] Impact of COVID-19 - The pandemic has led to increased recognition of domestic brands and a shift in consumer preferences towards local products [5] - The company has been designated as a key supplier during the pandemic, contributing to public health efforts [5] - Post-pandemic, the company aims to leverage increased consumer focus on health and immunity to enhance its market position [5]

Financial Performance - In 2021, the company achieved a revenue of CNY 2.54 billion, with a net profit of CNY 73.31 million, representing a growth of 122.61% compared to 2020 [2] - In Q1 2022, the company reported a revenue of CNY 814 million, a year-on-year increase of 43.68%, and a net profit of CNY 20.13 million, also showing growth [2] Product Development and Sales - The company has successfully launched the main product "Aijia" and the new product "Keruixin," which have shown strong sales performance since 2022 [3] - The "Keruixin" product has gained consumer recognition due to its excellent formula and high cost-performance ratio, leading to a high repurchase rate [3] Market Strategy and Adaptation - The company has adapted to the challenges posed by the pandemic by ensuring the supply of raw materials and maintaining production operations, thus safeguarding its performance [4] - The shift towards new retail channels has been effective, with the new retail model showing strong sales growth, particularly for the "Keruixin" product, which nearly matched the total sales of 2021 in April 2022 [4] Industry Outlook - The infant formula industry is expected to experience increased competition, with smaller brands likely to exit the market, leading to higher industry concentration [4] - The company anticipates structural growth opportunities due to supportive policies for childbirth and an expected rebound in newborn population numbers [5] Management and Operational Improvements - Following the return of the founder as General Manager, the company has implemented significant reforms aimed at improving profitability and operational performance [5] - Key strategies include optimizing organizational structure, enhancing cost control measures, and transitioning towards a new retail model to improve overall operational efficiency [5]

Financial Performance - The company's revenue for Q3 2022 was ¥802,854,226.97, representing a 49.62% increase compared to the same period last year[4] - The net profit attributable to shareholders decreased by 74.46% to ¥1,334,719.69, while the net profit excluding non-recurring items was -¥8,578,550.15, a 65.77% increase[4] - Sales revenue increased by 45.78% year-on-year, with a total increase of ¥759,146,200[10] - Net profit for the third quarter of 2022 was ¥47,172,900.31, representing an increase of 8.5% from ¥43,336,196.24 in the same period last year[27] - The net profit attributable to the parent company shareholders for Q3 2022 was ¥44,249,710.35, an increase from ¥38,749,901.96 in the same period last year, representing a growth of approximately 3.86%[28] - The total comprehensive income for Q3 2022 was ¥46,634,781.79, compared to ¥51,229,088.00 in Q3 2021, indicating a decrease of about 8.93%[28] Cash Flow and Liquidity - Operating cash flow for the year-to-date increased by 231.36% to ¥304,272,487.38[4] - Cash inflow from operating activities increased by 50.47% to ¥255,000,000, reflecting improved cash collection[12] - The operating cash flow for the period was ¥304,272,487.38, significantly higher than ¥91,825,044.89 in the previous year, marking an increase of approximately 231.36%[30] - Cash and cash equivalents at the end of Q3 2022 stood at ¥551,080,662.03, down from ¥640,302,877.54 at the beginning of the period, reflecting a decrease of about 13.88%[31] - The total cash inflow from operating activities was ¥2,547,418,295.48, compared to ¥1,692,950,522.51 in the previous year, showing an increase of approximately 50.53%[30] - The total cash outflow from operating activities was ¥2,243,145,808.10, up from ¥1,601,125,477.62, which is an increase of about 40.19%[30] - The net cash flow from investing activities was -¥89,291,451.91, a decrease from ¥239,712,088.55 in the same period last year, indicating a decline of approximately 137.24%[30] - The net cash flow from financing activities was -¥304,393,141.30, compared to -¥304,160,475.13 in the previous year, showing a slight increase in outflow[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,867,581,511.42, a decrease of 4.96% from the previous year[4] - The company's total assets as of September 30, 2022, amounted to ¥3,867,581,511.42, a decrease from ¥4,069,421,166.85 at the beginning of the year[24] - Current liabilities totaled ¥1,964,279,101.59, down 7.3% from ¥2,118,700,258.86 at the start of the year[24] - The company reported a decrease in total liabilities to ¥2,033,000,441.55 from ¥2,232,686,402.91 at the beginning of the year, a reduction of 8.9%[24] - The company's cash and cash equivalents decreased to ¥623,984,340.39 from ¥676,870,643.54 at the beginning of the year, reflecting a decline of 7.8%[24] - Inventory levels decreased to ¥365,008,925.70, down 28.0% from ¥505,645,822.70 at the beginning of the year[24] - Long-term equity investments increased to ¥125,798,201.76, up 7.3% from ¥117,505,055.87 at the beginning of the year[24] - The company's retained earnings showed an improvement, with a loss of ¥895,963,065.57 compared to a loss of ¥940,212,775.92 at the beginning of the year[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 67,614, with the largest shareholder, Beiyinmei Group Co., Ltd., holding 18.65% of shares[17] - Beiyinmei Group Co., Ltd. pledged 194.85 million shares and froze 44,200 shares, indicating significant financial maneuvers[17] - The company has repurchased a total of 15.76 million shares, accounting for 1.46% of the total share capital, which reflects a strategy to enhance shareholder value[18] Strategic Initiatives - The company is focused on expanding its market presence and enhancing its product offerings through strategic investments and partnerships[19] - The company is supporting the establishment of an industrial incubation fund by its wholly-owned subsidiary to strengthen the integration of industry and finance, aiming for future project acquisitions that align with its strategic development[19] - The company reported a significant decrease in investment income by 61.29%, amounting to a reduction of ¥11,634,800, due to the previous year's gains from the sale of a subsidiary[10] - The company transferred its wholly-owned subsidiary Guangxi Quanan Sheng Enterprise Management Co., Ltd. to a 48% stake, which is no longer included in the consolidated financial statements[20] - The company will calculate financial assistance interest at an annualized rate of 5% based on the actual amount and duration of funds used by Guangxi Quanan Sheng[20] Operational Efficiency - Operating costs rose by 99.66%, amounting to an increase of ¥782,229,600, primarily due to higher sales revenue[10] - Research and development expenses decreased by 39.20% to ¥1,484,000, indicating reduced investment in R&D[10] - The report indicates a need for improved cash flow management to counterbalance the significant decreases in cash flow from investment and financing activities[15] - The company is committed to timely disclosures regarding the progress of the industrial incubation fund and its associated projects[19] - Basic and diluted earnings per share remained stable at ¥0.04 for both Q3 2022 and Q3 2021[28] - The company reported a decrease in other comprehensive income, with a net amount of -¥538,118.52 for Q3 2022, compared to ¥7,892,891.76 in the same period last year[28]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥1.61 billion, representing a 43.95% increase compared to ¥1.12 billion in the same period last year[23]. - The net profit attributable to shareholders of the listed company was approximately ¥42.91 million, an increase of 28.01% from ¥33.52 million in the previous year[23]. - The net profit after deducting non-recurring gains and losses was approximately ¥27.36 million, reflecting a significant increase of 60.08% compared to ¥17.09 million in the same period last year[23]. - The net cash flow from operating activities reached approximately ¥186.10 million, a substantial increase of 412.18% from ¥36.34 million in the previous year[23]. - Basic earnings per share increased to ¥0.04, up 33.33% from ¥0.03 in the same period last year[23]. - Total revenue for the reporting period reached ¥1,614,360,138.82, representing a year-on-year increase of 43.95% compared to ¥1,121,481,666.83 in the same period last year[57]. - The company reported a net profit of ¥43,843,803.37 for the first half of 2022, compared to ¥38,065,464.65 in the same period of 2021, marking an increase of 15.5%[168]. - The total comprehensive income for the first half of 2022 was ¥43,719,463.40, compared to ¥40,962,410.80 in the previous year, an increase of 4.3%[168]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥4.08 billion, a slight increase of 0.26% from ¥4.07 billion at the end of the previous year[23]. - The net assets attributable to shareholders of the listed company were approximately ¥1.83 billion, reflecting a 2.43% increase from ¥1.79 billion at the end of the previous year[23]. - Total liabilities decreased slightly to ¥2,208,656,753.35 from ¥2,232,686,402.91, a decrease of approximately 1.1%[160]. - Total current assets increased to ¥2,206,368,524.58 as of June 30, 2022, from ¥2,183,321,715.52 at the beginning of the year, reflecting a growth of approximately 1.2%[158]. - The total equity of the company increased to ¥2,116,247,124.94 from ¥2,092,842,220.38, showing a growth of 1.1%[167]. Revenue Segments - Revenue from the milk powder segment was ¥1,190,471,160.39, accounting for 73.74% of total revenue, with a year-on-year growth of 18.20%[58]. - The sales revenue of children's powder increased by 286% year-on-year, while the sales of special medical formula milk powder grew by over 62.40%[36]. - E-commerce revenue amounted to ¥204,418,972.81, with a year-on-year increase of 12.48% in sales volume[43]. - The sales volume of milk powder increased by 30.64% to 10,396.19 tons, while production volume rose by 31.17% to 10,921.96 tons[45]. Investments and R&D - The total investment amount during the reporting period was ¥99,316,390.81, representing a significant increase of 226.84% compared to ¥30,386,666.80 in the same period last year[72]. - The company has 21 invention patents and 60 registered formula products for infant formula milk powder, showcasing its strong R&D capabilities[47]. - Research and development expenses decreased by 28.95% to ¥10,698,461.48 from ¥15,058,142.75[54]. - The company is focusing on expanding its ODM and OEM business to optimize its industrial structure and improve capacity utilization[36]. Market Strategy and Operations - The company has strengthened its marketing strategy and operational efficiency under the leadership of its founder, laying a solid foundation for future growth[36]. - The online and offline integration of the new retail business model is being emphasized, with sales through e-commerce platforms like JD and Tmall[39]. - The company plans to continue expanding its product offerings and market presence, focusing on innovation in new product development and technology[62]. Risks and Challenges - The company has highlighted potential risks and countermeasures in its future development outlook[5]. - The company continues to explore precise nutrition formula products and other related services to mitigate risks from declining newborn population[86]. - The company is actively managing supply chain risks and inventory control to mitigate related risks and develop effective alternatives[87]. - The company is closely monitoring the impact of the pandemic and is committed to employee health and safety while leveraging its R&D and production capabilities to support pandemic prevention efforts[87]. Shareholder Information - The total number of shares increased to 1,080,043,333, with 57,517,858 shares being newly issued, representing 5.33% of the total before the change[137]. - The company’s major shareholder, Beiyinmei Group, reduced its holdings by 10.8 million shares, now holding 201,418,500 shares, which is 18.65% of the total[138]. - The largest shareholder, Beining Group Co., Ltd., holds 19.65% of the shares, totaling 212,218,500 shares, with 194,894,200 shares pledged[145]. - The company has repurchased a total of 8,286,307 shares, accounting for 0.77% of the total share capital[145]. Legal and Compliance - The total amount involved in economic disputes where the company is the plaintiff is CNY 26.46 million, with no expected liabilities[108]. - The total amount involved in economic disputes where the company is the defendant is CNY 38.45 million, currently under court review[108]. - The company has frozen 4,466,576 shares held by its controlling shareholder, accounting for 0.41% of the total share capital, due to a court ruling[109].

Financial Performance - The company's revenue for Q1 2022 was ¥814,448,112.17, representing a 43.68% increase compared to ¥566,858,555.71 in the same period last year[4] - Net profit attributable to shareholders was ¥20,126,374.67, up 38.45% from ¥14,537,381.04 year-on-year[4] - The net profit excluding non-recurring gains and losses surged by 266.35% to ¥15,517,744.73 from ¥4,235,790.79 in the previous year[4] - Basic earnings per share doubled to ¥0.02 from ¥0.01 year-on-year[4] - Net profit for Q1 2022 reached ¥20,984,457.67, representing a 11.6% increase from ¥18,810,095.29 in Q1 2021[24] - The net profit attributable to the parent company was ¥20,126,374.67, compared to ¥14,537,381.04 in the same period last year, marking a growth of 38.5%[24] - Basic and diluted earnings per share for Q1 2022 were both ¥0.02, up from ¥0.01 in Q1 2021[24] Cash Flow and Liquidity - Operating cash flow increased by 145.02% to ¥52,895,828.43, compared to ¥21,588,202.87 in the same quarter last year[4] - The net cash flow from operating activities increased by ¥31,307.6 million, reflecting a growth of 145.02% year-on-year[11] - The net cash flow from operating activities for the current period is ¥52,895,828.43, an increase of 144.5% compared to ¥21,588,202.87 in the previous period[26] - Total cash inflow from operating activities reached ¥843,266,621.84, up from ¥631,773,462.88, reflecting a growth of 33.4%[26] - Cash outflow from operating activities was ¥790,370,793.41, compared to ¥610,185,260.01 in the previous period, indicating an increase of 29.5%[26] - The ending balance of cash and cash equivalents is ¥606,082,937.03, down from ¥640,302,877.54, a decrease of 5.4%[27] - The company received ¥250,000,000.00 in borrowings, a decrease from ¥300,000,000.00 in the previous period[27] - Cash received from other financing activities was ¥206,813,283.34, compared to ¥332,522,663.54 previously, reflecting a decline of 37.7%[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,112,136,081.48, a 1.05% increase from ¥4,069,421,166.85 at the end of the previous year[4] - The company's equity attributable to shareholders rose by 0.93% to ¥1,802,455,204.51 from ¥1,785,836,479.80 at the end of the last year[4] - Total liabilities as of the end of Q1 2022 were ¥2,257,924,509.83, slightly up from ¥2,232,686,402.91 at the end of Q1 2021[20] - Short-term borrowings rose to CNY 1,111,156,125.70 from CNY 1,011,350,119.07, indicating an increase of approximately 9.9%[19] Investments and Joint Ventures - The company established a joint venture, Yibei Intelligent (Hangzhou) Nutrition Technology Co., Ltd., with a registered capital of CNY 10 million, where the company holds a 40% stake[16] - The company’s long-term equity investments increased from CNY 117,505,055.87 to CNY 122,295,456.64, reflecting a growth of approximately 4.7%[19] Inventory and Receivables - The company reported a significant increase in accounts receivable, which decreased by 48.51%, while prepayments surged by 152.41%[8] - The accounts receivable decreased slightly from CNY 741,811,792.81 to CNY 738,009,158.53, a marginal decline of about 0.4%[18] - Inventory decreased significantly from CNY 505,645,822.70 to CNY 395,590,039.67, a reduction of about 21.8%[19] Operating Costs and Expenses - Total operating costs for Q1 2022 were ¥773,542,287.77, up 42.4% from ¥543,555,353.94 in Q1 2021[23] - Research and development expenses for Q1 2022 were ¥4,553,454.36, a slight decrease from ¥4,754,671.25 in Q1 2021[23] Comprehensive Income - The company reported a total comprehensive income of ¥17,142,007.71 for Q1 2022, compared to ¥17,413,766.62 in Q1 2021[24]